JP2016510309A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510309A5
JP2016510309A5 JP2015547567A JP2015547567A JP2016510309A5 JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5 JP 2015547567 A JP2015547567 A JP 2015547567A JP 2015547567 A JP2015547567 A JP 2015547567A JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5
Authority
JP
Japan
Prior art keywords
polypeptide
mer
axl
tyro3
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015547567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510309A (ja
JP6345690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/074786 external-priority patent/WO2014093690A1/en
Publication of JP2016510309A publication Critical patent/JP2016510309A/ja
Publication of JP2016510309A5 publication Critical patent/JP2016510309A5/ja
Application granted granted Critical
Publication of JP6345690B2 publication Critical patent/JP6345690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015547567A 2012-12-14 2013-12-12 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用 Active JP6345690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14
US61/737,276 2012-12-14
PCT/US2013/074786 WO2014093690A1 (en) 2012-12-14 2013-12-12 Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098435A Division JP6832887B2 (ja) 2012-12-14 2018-05-23 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用

Publications (3)

Publication Number Publication Date
JP2016510309A JP2016510309A (ja) 2016-04-07
JP2016510309A5 true JP2016510309A5 (cg-RX-API-DMAC7.html) 2017-02-02
JP6345690B2 JP6345690B2 (ja) 2018-06-20

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015547567A Active JP6345690B2 (ja) 2012-12-14 2013-12-12 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用
JP2018098435A Expired - Fee Related JP6832887B2 (ja) 2012-12-14 2018-05-23 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018098435A Expired - Fee Related JP6832887B2 (ja) 2012-12-14 2018-05-23 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用

Country Status (11)

Country Link
US (3) US9822347B2 (cg-RX-API-DMAC7.html)
EP (2) EP3326622B1 (cg-RX-API-DMAC7.html)
JP (2) JP6345690B2 (cg-RX-API-DMAC7.html)
AU (3) AU2013359179B2 (cg-RX-API-DMAC7.html)
CA (1) CA2894539C (cg-RX-API-DMAC7.html)
DK (2) DK2931265T6 (cg-RX-API-DMAC7.html)
ES (2) ES2862335T3 (cg-RX-API-DMAC7.html)
FI (1) FI2931265T6 (cg-RX-API-DMAC7.html)
NO (1) NO3049208T3 (cg-RX-API-DMAC7.html)
PT (2) PT3326622T (cg-RX-API-DMAC7.html)
WO (1) WO2014093690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011207381B2 (en) * 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
PT3326622T (pt) * 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6
MX2020007130A (es) * 2017-11-04 2021-02-15 Aravive Biologics Inc Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
EP4398937A4 (en) * 2021-09-11 2025-07-09 Aravive Inc METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032103A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2004092735A2 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Axlリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
CA2630475A1 (en) 2004-11-24 2006-06-01 The Regents Of The University Of Colorado Mer diagnostic and therapeutic agents
CA2607133A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US8168415B2 (en) * 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
US8841424B2 (en) * 2009-05-11 2014-09-23 U3 Pharma Gmbh Humanized AXL antibodies
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011207381B2 (en) * 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011326164B2 (en) 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013090776A1 (en) * 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
PT3326622T (pt) * 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6

Similar Documents

Publication Publication Date Title
JP2016510309A5 (cg-RX-API-DMAC7.html)
JP2016000731A5 (cg-RX-API-DMAC7.html)
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
WO2018098363A3 (en) Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
RU2018132044A (ru) Антитела против тау
NL300919I2 (nl) Brodalumab
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
JP2014043446A5 (cg-RX-API-DMAC7.html)
JP2019514361A5 (cg-RX-API-DMAC7.html)
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
CA2953714C (en) Anti-tnfa antibodies with ph-dependent antigen binding
JP2015212284A5 (cg-RX-API-DMAC7.html)
MX384984B (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
HK1198832A1 (en) Fn14 binding proteins and uses thereof
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JP2017518072A5 (cg-RX-API-DMAC7.html)
EP3339322A3 (en) Immunoglobulin single variable domain antibodies with a c-terminal extension for reduced immunogenicity
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
JP2017529870A5 (cg-RX-API-DMAC7.html)
WO2007146401A3 (en) Denatured collagen peptides and uses thereof